水凝胶在青光眼缓控释递药中的研究进展

摘要：目的 建立一种蒺藜甾体皂苷含量测定和外观颜色均匀性检测方法来优化炒蒺藜炮制工艺。方法 以LC-QQQ/MS测定蒺藜呋甾皂苷B和蒺藜皂苷K的总含量作为化学指标，采用色彩色差仪测定炒蒺藜饮片总色值E* ab，以30次随机抽取样品E* ab值的RSD值作为外观颜色均匀性指标。在此基础上，采用L9(34)正交实验法，以炒制温度、炒制时间和炒药机转速为考察因素，优选炒蒺藜饮片的炮制工艺。结果 蒺藜呋甾皂苷B和蒺藜皂苷K均具有良好的线性关系(r>0.999)，检测限分别为1.28 ng·mL-1和10.44 ng·mL-1，定量限分别为5.40 ng·mL-1和27.81 ng·mL-1，精密度、24 h稳定性、重复性试验的RSD均＜3.0%，平均加样回收率分别为96.66%和97.10%。色差技术可为炒蒺藜外观颜色均匀性提供客观化的数值。炒蒺藜最佳炮制工艺为200 ℃以60 r·min-1转速炒制15 min。结论 LC-QQQ/MS法结合色差技术所优选的蒺藜炒制工艺稳定可行，可为其他中药炮制工艺优化提供参考。

Research Progress on Hydrogel-based Sustained and Controlled Drug Delivery for Glaucoma

OBJECTIVE To screen the marker target protein of T2DM based on hepatic gluconeogenesis inhibition strategy. METHODS The microarray data set of human liver tissue was downloaded from NCBI database. T2DM susceptibility genes were analyzed online and screened using GEO2R, and gluconeogenesis-related targets were searched using GeneCards and OMIM databases. Then the interaction targets between T2DM and hepatic gluconeogenesis were screened. The interaction network model of interaction targets was constructed to analyze and screen the marker target proteins. Gene ontology and KEGG pathway enrichment analysis were performed in Metascape database. Finally, the molecular docking of T2DM drugs with the marker target proteins was carried out. RESULTS a total of 1143 T2DM susceptibility genes and 958 gluconeogenesis related targets were identified, and 56 targets for interaction between T2DM and hepatic gluconeogenesis were obtained. Two marker target proteins PTPRC and VCAM1 were screened by network analysis. The targets were mainly concentrated in glucose catabolic process, canonical glycolysis, glycolytic process through glucose-6-phosphate, and other biological processes. The targets were focused on working through pathways such as Glycolysis/Gluconeogenesis, AGE-RAGE signaling pathway in diabetic complications, and Endocrine resistance. The 26 hypoglycemic drugs all have good spatial matching, energy matching and strong binding ability with marker targets. CONCLUSION We systematically screened two marker target proteins in human liver tissue that may affect hepatic gluconeogenesis in T2DM, and revealed the regulatory pathway of hepatic gluconeogenesis in T2DM, which provided the basis for further studying the mechanism of prevention and treatment of hepatic gluconeogenesis and looking for new targets of hypoglycemic drugs.